Cormedix Sees FY2025 Sales $390.000M-$410.000M vs $283.692M Est

CorMedix Inc. -0.75%

CorMedix Inc.

CRMD

10.56

-0.75%

  • CorMedix again raises its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, and fourth quarter net revenue guidance to a range of $115 to $135 million. In addition, the Company is increasing its guidance for fully synergized pro forma adjusted EBITDA for 2025 to a range of $220 – $240 million(3).
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via